NIH Requests Comment on Genomic Data Sharing Policy Draft
By Nicolle Strand,
The Blog of the Presidential Commission for the Study of Bioethical Issues
| 10. 23. 2013
Last month, the National Institutes of Health (NIH) published a draft version of its new
genomic data sharing policy, along with a
request for public comment. The draft policy parallels some of the concepts and recommendations discussed in the Presidential Commission for the Study of Bioethical Issues’ (Bioethics Commission) 2012 report:
Privacy and Progress in Whole Genome Sequencing. The Bioethics Commission is pleased to note that several of its recommendations and core ethical principles are shared by NIH and
other law and policymakers.
The Bioethics Commission’s recommends in
Privacy and Progress (Recommendation 1.1) that “Funders of whole genome sequencing research… should maintain or establish clear policies defining acceptable access to and permissible uses of whole genome sequence data.” The NIH draft policy does just that: it defines the requirements for access to and use of genomic data, and sets forth the guiding ethical principles for the responsible use of such data.
The NIH draft policy states its purpose as encouraging broad sharing of genomic data, in order to facilitate important advancements in medicine, while also ensuring...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...